Effects of roux-en-y gastric bypass or diabetes support and education on insulin sensitivity and insulin secretion in morbidly obese patients with type 2 diabetes

Annals of Surgery

Volumn 259, Issue 3, 2014, Pages 494-501

  Khoo, Chin Meng ^a,b   Chen, Jiegen ^a   Pamuklar, Zehra ^a   Torquati, Alfonso ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

cell function; insulin sensitivity; morbid obesity; Roux en Y gastric bypass; type 2 diabetes mellitus

Indexed keywords

ABSORPTIOMETRY, PHOTON; BLOOD GLUCOSE; BODY COMPOSITION; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GASTRIC BYPASS; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; OBESITY, MORBID; PATIENT EDUCATION AS TOPIC; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84894088875     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e318294d19c     Document Type: Article

References (30)

1. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999-2008. JAMA. 2010;303:235-241.
2. Rogers RG, Hummer RA, Krueger PM. The effect of obesity on overall, circulatory disease-and diabetes-specific mortality. J Biosoc Sci. 2003;35: 107-129. (Pubitemid 36068148)
3. Powell MS, Fernandez AZ, Jr. Surgical treatment for morbid obesity: the laparoscopic Roux-en-Y gastric bypass. Surg Clin North Am. 2011;91: 1203-1224.
4. Dixon JB, Zimmet P, Alberti KG, et al. Bariatric surgery: an IDF statement for obese Type 2 diabetes. Arq Bras Endocrinol Metabol. 2011;55:367-382.
5. Lin E, Liang Z, Frediani J, et al. Improvement in β-cell function in patients with normal and hyperglycemia following Roux-en-Y gastric bypass surgery. Am J Physiol Endocrinol Metab. 2010;299:E706-E712.
6. Camastra S, Gastaldelli A, Mari A, et al. Early and longer termeffects of gastric bypass surgery on tissue-specific insulin sensitivity and beta cell function in morbidly obese patients with and without type 2 diabetes. Diabetologia. 2011;54:2093-2102.
7. Kadera BE, Lum K, Grant J, et al. Remission of type 2 diabetes after Roux-en-Y gastric bypass is associated with greater weight loss. Surg Obes Relat Dis. 2009;5:305-309.
8. Torquati A, Lutfi R, Abumrad N, et al. Is Roux-en-Y gastric bypass surgery the most effective treatment for type 2 diabetes mellitus in morbidly obese patients? JGastrointest Surg. 2005;9:1112-1116; discussion 1117-1118.
9. Unick JL, Beavers D, Jakicic JM, et al. Effectiveness of lifestyle interventions for individuals with severe obesity and type 2 diabetes: results from the Look AHEAD trial. Diabetes Care. 2011;34:2152-2157.
10. Genuth S, Alberti KG, Bennett P, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26:3160-3167.
11. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventionalmedical therapy for type 2 diabetes. N Engl JMed. 2012;366:1577-1585.
12. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366: 1567-1576.
13. Isbell JM, Tamboli RA, Hansen EN, et al. The importance of caloric restriction in the early improvements in insulin sensitivity after Roux-en-Y gastric bypass surgery. Diabetes Care. 2010;33:1438-1442.
14. Plum L, Ahmed L, Febres G, et al. Comparison of glucostatic parameters after hypocaloric diet or bariatric surgery and equivalent weight loss. Obesity (Silver Spring). 2011;19:2149-2157.
15. Fonseca VA. Defining and characterizing the progression of type 2 diabetes. Diabetes Care. 2009;32(suppl 2):S151-S156.
16. Finegood DT, Topp BG. Beta-cell deterioration-prospects for reversal or prevention. Diabetes Obes Metab. 2001;3(suppl 1):20-27.
17. Bays H, Mandarino L, DeFronzoRA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetesmellitus: peroxisomal proliferatoractivated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab. 2004;89:463-478. (Pubitemid 38269844)
18. Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on betacell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet. 2008;371: 1753-1760. (Pubitemid 351697950)
19. Schaffer JE. Lipotoxicity: when tissues overeat. Curr Opin Lipidol. 2003;14:281-287. (Pubitemid 36688207)
20. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes. 1997;46:3-10. (Pubitemid 27009941)
21. Santomauro AT, Boden G, Silva ME, et al. Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes. 1999;48:1836-1841. (Pubitemid 29415205)
22. VisserM, Bouter LM,McQuillan GM, et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282:2131-2135.
23. FestaA, D'AgostinoR, Jr, Howard G, et al.Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102:42-47. (Pubitemid 30430551)
24. Selvin E, Paynter NP, Erlinger TP. The effect of weight loss on C-reactive protein: a systematic review. Arch Intern Med. 2007;167:31-39. (Pubitemid 46072404)
25. Monte SV, Caruana JA, Ghanim H, et al. Reduction in endotoxemia, oxidative and inflammatory stress, and insulin resistance after Roux-en-Y gastric bypass surgery in patients with morbid obesity and type 2 diabetes mellitus [published online ahead of print November 16, 2011]. Surgery. 2012;151:587-593. doi:10.1016/j.surg.2011.09.038.
26. Funnell MM, Brown TL, Childs BP, et al. National standards for diabetes self-management education. Diabetes Care. 2009;32(suppl 1):S87-S94.
27. Pi-Sunyer X, Blackburn G, Brancati FL, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care. 2007;30:1374-1383. (Pubitemid 46871141)
28. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes. 1995;44:1249-1258.
29. Festa A, Williams K, D'Agostino R, Jr, et al. The natural course of betacell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study. Diabetes. 2006;55:1114-1120. (Pubitemid 44100189)
30. Nannipieri M, Mari A, Anselmino M, et al. The role of beta-cell function and insulin sensitivity in the remission of type 2 diabetes after gastric bypass surgery. J Clin Endocrinol Metab. 2011;96:E1372-E1379.